The findings suggest that the association between FSH and cardiometabolic risk factors may be independent of age, estrogen, and body weight, and lower FSH levels independently increase odds of the development of cardiometabolic risk and MetS in menopausal women. Here, BRD2 is linked to metabolic syndrome.